Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

NCT02898207 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Metastatic High Grade Fallopian Tube Serous Adenocarcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Primary Peritoneal Serous Adenocarcinoma
Metastatic Triple-Negative Breast Carcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Breast Carcinoma
Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
Recurrent High Grade Ovarian Serous Adenocarcinoma
Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Triple-Negative Breast Carcinoma
Refractory Fallopian Tube Serous Adenocarcinoma
Refractory Ovarian Serous Adenocarcinoma
Refractory Primary Peritoneal Serous Adenocarcinoma
Refractory Triple-Negative Breast Carcinoma
Unresectable High Grade Fallopian Tube Serous Adenocarcinoma
Unresectable Malignant Solid Neoplasm
Unresectable Primary Peritoneal Serous Adenocarcinoma

Interventions

DRUG: Olaparib
DRUG: Onalespib

Sponsor

National Cancer Institute (NCI)